$MRK Company News Dow industrials suffer worst drop since

New Post Public Reply Private Reply Replies (0) Message Board

Jan 25, 2014 at 10:15 AM

$MRK Company News

Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Beam up on Suntory deal; Elliott report lifts Juniper 4:17 p.m. Jan. 13, 2014 - Saumya Vaishampayan
Merck shares hit 52-week high on drug hopes, plans for cutbacks 12:31 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Merck initiates melanoma filing with FDA 11:45 a.m. Jan. 13, 2014 - Tess Stynes
Merck shares rise 3%, best on Dow average 9:41 a.m. Jan. 13, 2014 - Laura Mandaro
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - blogs.marketwatch.com
Cholesterol drugs: Do you need them, or not? 5:00 a.m. Jan. 8, 2014 - Elizabeth O'Brien
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Merck, Twitter, Apple are stocks to watch 4:34 p.m. Dec. 29, 2013 - Wallace Witkowski
Merck to revamp its R&D practices: WSJ 4:49 p.m. Dec. 27, 2013 - Wallace Witkowski
Merck to radically reshape R&D unit: WSJ 4:40 p.m. Dec. 27, 2013 - Wallace Witkowski
Not all pharmaceuticals are created equal 12:39 p.m. Dec. 26, 2013 - The Trading Deck
EU approves Merck's Erbitux for cancer treatment 4:52 a.m. Dec. 23, 2013 - MarketWatch.com
Biotechs continue to pay off 10:27 a.m. Dec. 20, 2013 - The Trading Deck
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Merck, McDonald's are top decliners in Dow index 4:05 p.m. Dec. 4, 2013 - Polya Lesova
Cuts, stock buyback, acquisition combine to boost Forest shares 11:09 a.m. Dec. 2, 2013 - blogs.marketwatch.com
Merck, J.P. Morgan lead Dow decliners 9:35 a.m. Nov. 13, 2013 - Laura Mandaro
Merck, Cisco lead gainers in Dow industrials 4:03 p.m. Nov. 12, 2013 - Polya Lesova
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com

Five Big Stocks That Escaped The Market Carnage Sell-Off 7:28 a.m. Today - 247WallSt.com
5 New Drugs That Could Be Blockbusters in 2014 3:42 a.m. Today - Barrons.com
Focus On Cancer Immunotherapy Results 3:41 a.m. Today - Seeking Alpha
Big Pharmas Battle For The Billion-Dollar Melanoma Market 6:42 p.m. Jan. 24, 2014 - Seeking Alpha
Dow Today: Merck (MRK) Leads The Day Higher, Visa (V) Lags 4:30 p.m. Jan. 24, 2014 - TheStreet.com
Amgen Reports Positive Evolocumab Data - Analyst Blog 4:30 p.m. Jan. 24, 2014 - Zacks.com
Do Patent Expirations Mean Fewer Jobs At Novartis? 10:26 a.m. Jan. 24, 2014 - Wall St. Cheat Sheet
Turbocharged Dividends 8:05 a.m. Jan. 24, 2014 - Barrons.com
Cramer's Mad Money - It's All About Icahn (1/23/14) 5:56 a.m. Jan. 24, 2014 - Seeking Alpha
The Obsolescence of Provectus' Skin Cancer Drug Means Current Speculative Run Ends Badly 11:26 a.m. Jan. 23, 2014 - TheStreet.com
Bristol-Myers' New Nivolumab Trial Sparks Worries 10:15 a.m. Jan. 23, 2014 - Investors Business Daily
Drugmaker Merck Tries To Jump-Start Slow Growth 4:50 p.m. Jan. 22, 2014 - Investors Business Daily
5 Stocks That Dominated The Market Wednesday 3:34 p.m. Jan. 22, 2014 - 247WallSt.com
Johnson & Johnson Balances Earnings Beat With Modest Guidance 9:23 a.m. Jan. 21, 2014 - Wall St. Cheat Sheet
Buy Recommendation Reiterated For Merck & Co Inc 9:05 a.m. Jan. 21, 2014 - TheStreet.com
How Big Are Emerging Markets? 8:32 a.m. Jan. 21, 2014 - GuruFocus.com
Will 'Dogs of the Dow' ETF Continue to Shine in 2014? - ETF News And Commentary 7:45 a.m. Jan. 21, 2014 - Zacks.com
J&J Needs to Earn Investor Loyalty 1:30 p.m. Jan. 20, 2014 - WSJ.com
GCVRZ: Betting On The Sales Of Lemtrada In A Moving MS Drug Market 2:05 p.m. Jan. 19, 2014 - Seeking Alpha
Forest Laboratories - Aptalis Deal Sparks More Enthusiasm 4:20 a.m. Jan. 19, 2014 - Seeking Alpha

RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics 10:06 a.m. Jan. 24, 2014 - ACCESSWIRE
ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet 8:05 a.m. Jan. 24, 2014 - GlobeNewswire
Formex CSO Blair West to Speak at 3rd Drug Formulation & Bioavailability Conference 10:00 a.m. Jan. 23, 2014 - PR Newswire - PRF
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
John Daly, Previous Merck Exec., Offers Consulting Tips 6:35 p.m. Jan. 17, 2014 - Marketwire
Sanford Heisler Adds Four New Class Representatives To $250M Gender Discrimination Class Action Suit Against Pharma Giant Merck 10:03 a.m. Jan. 17, 2014 - PR Newswire - PRF
Trimel Announces Appointment of Tom Rossi to Its Board of Directors 5:08 p.m. Jan. 16, 2014 - Marketwire
Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine 6:59 p.m. Jan. 15, 2014 - BusinessWire - BZX
Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference 8:35 a.m. Jan. 13, 2014 - BusinessWire - BZX
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck 9:00 p.m. Jan. 12, 2014 - BusinessWire - BZX
Biotech Investing Strategies in 2014 Is Key Topic Bringing Investors to San Francisco for Biotech Showcase(TM) 2014 Next Week, January 13 10:59 a.m. Jan. 9, 2014 - BusinessWire
Dako to collaborate with Merck on development of companion diagnostics for cancer treatment 9:16 a.m. Jan. 9, 2014 - GlobeNewswire
Dako to collaborate with Merck on development of companion diagnostics for cancer treatment 9:00 a.m. Jan. 9, 2014 - Thomson Reuters ONE
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension 8:29 a.m. Jan. 8, 2014 - BusinessWire
Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix 8:00 a.m. Jan. 8, 2014 - PR Newswire
Forma Therapeutics Appoints Christopher Dinsmore to Vice President, Medicinal and Computational Chemistry 8:00 a.m. Jan. 7, 2014 - BusinessWire
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
Merck to Hold Fourth-Quarter 2013 Sales and Earnings Conference Call on February 5 4:59 p.m. Jan. 6, 2014 - BusinessWire
Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma 7:00 a.m. Dec. 30, 2013 - Marketwire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beacon AI's Murdock Flies into the Future for USAF

Advancing AI in the Skies Nothing quite shakes up the aviation scene like a debut flight of a new AI system aboard real-deal military planes. Beacon AI is throwing down its AI pilot assistant system, Murdock, on the table—its pride and joy just completed five flights on KC-46A Pegasus craft, sanctioned by no less than the U.S. Air Force itself. Grit and Innovation: The...

Real-World Study Shows Viable Use of Tarlatamab

Breaking New Ground in Cancer Care There's a shift happening in the realm of cancer treatment, and OneOncology's latest study on tarlatamab is right at the forefront. Bringing advanced therapies closer to home isn't just a pipe dream anymore. This real-world study, unveiled at the 2026 ESMO Congress, underscores that administering tarlatamab in outpatient settings might...

Vanda's NEREUS Outperforms in GLP-1 Vomiting Study

A Surprising Breakthrough in Vomiting Prevention You don't need to be an old hand on Wall Street to see that when a biotech company rolls out positive trial results, ears perk up. Today, Vanda Pharmaceuticals' announcement that their NEREUS™ (tradipitant) drug aced Study 3601 is catching more eyes than initially expected. It's not just about hitting numbers; it's about...

Backroads Invites Families: Adventures Boost Bookings by 20%

Rediscovering Family Time Through Adventure When was the last time a winter vacation got you this fired up? Backroads, the trailblazer in active getaways, is bucking the trend of typical holiday madness. Families are ditching the usual gift-giving grind for something way more memorable: experiences that blend action with bonding across generations. Big Numbers, Big...

Experts Unite to Tackle Drowsy Driving at NSF Forum

Awareness With a Purpose Heads-up, folks: the National Sleep Foundation's bringing the cavalry on drowsy driving to Washington. It's almost surreal how often we ignore the sleepy-eyed driver next to us, isn't it? Yet, here we are, revving up for a gathering where they're gathering the nation's sharpest minds in sleep science and traffic safety under one roof. Why Drowsy...

FIU Cuba Poll: Cuban American Vote Leans GOP

Here we got the latest scoop from the 2026 FIU Cuba Poll, and boy, it's a wild ride. Picture this: 76% of Cuban Americans in South Florida aren't fans of Trump’s escalated deportations of Cubans sans criminal records, yet a solid 68% are sticking to their GOP guns come election season. Now, ain't that a head-scratcher? Cuban Americans and the GOP: A Complex Relationship...

Midland, Michigan Tops 2027 Retirement Destinations

Down-to-Earth Findings for Retirees in 2027 Look, when we're talking about settling down after years of the daily grind, it's crystal clear what folks really care about: not blowing through their savings in a heartbeat. No wonder Midland, Michigan, nailed the No. 1 spot yet again in U.S. News & World Report's 2027 Best Places to Retire. And this ain't just a fluke; they...

Spotlight on Disability Inclusivity: 10 Honorees Celebrated

Celebrating Champions of Inclusivity April 17, 2026 was a red-letter day for hope and progress in Garden Grove. The Regional Center of Orange County (RCOC) hosted its 29th annual Spotlight Awards, tipping their hats to ten trailblazing individuals and organizations. In a society where the marginalized often get left out of the success parade, these folks are ahead of the...

Sobi Q3 2026 Report Defies Economic Headwinds

Resilience in a Tough Market In a world where every finance report often feels like a gloomy weather forecast, Swedish Orphan Biovitrum AB, or Sobi for short, has come out swinging. They just dropped their Q3 2026 financials, and it's a breath of fresh air in these turbulent economic times. Sobi, primarily dealing in rare diseases, posted an impressive 16% revenue jump....

Total Play's Q3 2026: Subscriber Surge, Debt Down

Subscriber Growth Amidst Financial Hurdles Here’s the deal with Total Play's third-quarter results for 2026: they’ve got a mixed bag of numbers that’ll make any investor think twice. The headline is a hefty rise in subscribers—a net gain of 143,340 in the Residential segment thanks to their top-tier internet services. But don’t start cheering just...